LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
On September 24, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) announced that the first patient has been dosed in the Phase 2a clinical trial...
93 Views
LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
On August 14, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) filed form 10-Q with financial results for the second quarter of 2026. Since we...
94 Views
LABT: Initiating Coverage of Lakewood-Amedex Building a Next-Generation Antimicrobial Platform
We are initiating coverage of Lakewood-Amedex Biotherapeutics, Inc. (LABT) with a $12.00 valuation. Lakewood is a biopharmaceutical company...
83 Views
Lakewood-Amedex Biotherapeutics, Inc: Initiating Coverage - June 23, 2026
The company's lead clinical candidate, Nu-3, is being developed for the treatment of infected diabetic foot ulcers (iDFU), an indication affecting...
97 Views